Gilead Sciences, Inc. (GILD): Price and Financial Metrics
Gilead Sciences, Inc. (GILD)
Today's Latest Price: $60.21 USD
Updated Oct 21 6:55pm
Add GILD to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
GILD Stock Summary
- GILD has a higher market value than 97.42% of US stocks; more precisely, its current market capitalization is $75,486,744,318.
- GILD's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 307.83 -- higher than 88.8% of US-listed equities with positive expected earnings growth.
- The volatility of Gilead Sciences Inc's share price is greater than that of only 3.91% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to Gilead Sciences Inc are ATVI, ADI, BIIB, AMAT, and RACE.
- GILD's SEC filings can be seen here. And to visit Gilead Sciences Inc's official web site, go to www.gilead.com.
GILD Stock Price Chart Interactive Chart >
GILD Price/Volume Stats
| Current price | $60.21 | 52-week high | $85.97 |
| Prev. close | $60.55 | 52-week low | $59.85 |
| Day low | $59.90 | Volume | 7,493,700 |
| Day high | $60.49 | Avg. volume | 14,659,546 |
| 50-day MA | $64.65 | Dividend yield | 4.52% |
| 200-day MA | $71.15 | Market Cap | 75.49B |
Gilead Sciences, Inc. (GILD) Company Bio
Gilead Sciences is a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs. The Company's primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.
GILD Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $60.21 | $30.49 | -50% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Gilead Sciences Inc. To summarize, we found that Gilead Sciences Inc ranked in the 30th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 49.5%. As for the metrics that stood out in our discounted cash flow analysis of Gilead Sciences Inc, consider:
- The company's compound free cash flow growth rate over the past 5.45 years comes in at -0.06%; that's greater than merely 17.6% of US stocks we're applying DCF forecasting to.
- The company has produced more trailing twelve month cash flow than 93.51% of its sector Healthcare.
- Gilead Sciences Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -51% |
| 1% | -50% |
| 2% | -50% |
| 3% | -49% |
| 4% | -49% |
| 5% | -48% |
Want more companies with a valuation profile/forecast similar to that of Gilead Sciences Inc? See CPIX, LMAT, HAPP, ILMN, and ZTS.
Loading social stream, please wait...